Search

Memorial Sloan Kettering Cancer Center feted three gifted young investigators for their insightful contributions to cancer research in a public symposium on December 1, 2011.

… Thursday, March 1, 2012 Summary Memorial Sloan Kettering Cancer Center feted three gifted young investigators for their insightful contributions to cancer research in a public symposium on December 1, 2011. Memorial Sloan Kettering Cancer Center feted three gifted young investigators for their insightful

Learn about MSK's new Program for Drug Development in Leukemia (PDD-L), which will offer more clinical trials for many types of leukemia.

… Monday, September 30, 2019 Summary MSK’s new Program for Drug Development in Leukemia (PDD-L) will offer more clinical trials for many types of leukemia. On September 3, Memorial Sloan Kettering launched the Program for Drug Development in Leukemia (PDD-L). This new program will focus on creating more

Read up on the progress being made in several key areas of cancer research, including immunotherapy, targeted therapy, precision surgery, and epigenetics.

… Wednesday, June 7, 2017 Summary Memorial Sloan Kettering researchers contributed more than 180 abstracts to this year’s ASCO meeting. Their scientific contributions are advancing the treatment options for all types of cancer. The annual meeting of the American Society of Clinical Oncology (ASCO) wrapped

MSK physician-scientists presented breakthrough advances in new treatment approaches for several cancer types at the 2024 ASCO Annual Meeting.

… Tuesday, June 4, 2024 Memorial Sloan Kettering Cancer Center (MSK) researchers presented breakthrough advances in new treatment approaches for several cancer types at the 2024 ASCO Annual Meeting held May 31 to June 4, 2023, in Chicago. Highlights of practice-changing study results in HPV-associated

Young women with breast cancer who receive neoadjuvant chemotherapy are more likely to decline referral to reproductive endocrinology and infertility specialists than women who receive adjuvant chemotherapy.

… Tuesday, September 8, 2020 Young women with breast cancer who receive neoadjuvant chemotherapy (NAC) are more likely to decline referral to reproductive endocrinology and infertility (REI) specialists than women who receive adjuvant chemotherapy, according to our retrospective study published recently

Radiation therapy after surgery can sharply reduce the chance that certain low-risk breast cancers will return.

… Sunday, October 21, 2018 Summary Ductal carcinoma in situ (DCIS) is a low-risk form of early-stage breast cancer . Women with DCIS can have radiation after the tumor is removed to lower the risk that the cancer could come back. A new study provides more evidence that radiation after surgery can greatly

The US Food and Drug Administration announced today that the drug ipilimumab (brand name Yervoy) has been approved for the treatment of patients with metastatic melanoma. It is the first drug ever shown to improve overall survival for patients with advanced melanoma.

… Friday, March 25, 2011 Memorial Sloan Kettering Researchers Played Key Roles in the Development of Ipilimumab The US Food and Drug Administration announced today that the drug ipilimumab (brand name Yervoy) has been approved for the treatment of patients with metastatic melanoma . It is the first drug

The word “epigenetic” literally means “above the genes.” Calico cats demonstrate a type of epigenetic inheritance called X-inactivation.

… Tuesday, June 19, 2018 If you’ve ever known a set of identical twins, you might have been struck by what they didn’t have in common. Maybe one was a skilled musician, while the other couldn’t carry a tune. Maybe one craved adventure, while the other preferred the couch. These anecdotal examples reveal

Learn how MSK researchers led the way in the approval of a new mantle cell lymphoma CAR T cell treatment.

… Wednesday, July 31, 2024 Mantle cell lymphoma (MCL) is a rare and sometimes ruthless form of  non-Hodgkin lymphoma . Even when treatment appears to be successful, the cancer often returns and is difficult to cure. A new therapy has been approved by the U.S. Food and Drug Administration (FDA) for these

Memorial Sloan Kettering Cancer Center (MSK) today announced the establishment of The Starr Foundation Program for Discovery Science, a pioneering new initiative made possible by a generous $50 million gift from The Starr Foundation. The program will support the visionary work of scientists at the Sloan Kettering Institute (SKI), the research arm of MSK, by funding foundational laboratory research that will drive the next generation of cancer breakthroughs and ultimately improve the lives of people facing cancer around the world.

… Tuesday, April 19, 2022 Memorial Sloan Kettering Cancer Center (MSK) today announced the establishment of The Starr Foundation Program for Discovery Science, a pioneering new initiative made possible by a generous $50 million gift from The Starr Foundation . The program will support the visionary work